Phase II Study of Pembrolizumab (MK-3475) in Combination With Standard Therapy for Newly Diagnosed Glioblastoma

Trial Profile

Phase II Study of Pembrolizumab (MK-3475) in Combination With Standard Therapy for Newly Diagnosed Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Temozolomide (Primary)
  • Indications Astrocytoma; Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 28 Aug 2017 Planned initiation date changed from 31 Jul 2017 to 31 Oct 2017.
    • 27 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top